Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
What this does not mean: agree can mean only that sources print the same normalized reading; it is not clinical-context equivalence, independent replication, or proof. differ requires matching structured context and disjoint comparable values. not_comparable and insufficient_context are not disagreement.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 841–850 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 841
- Medicine slug
- levetiracetam
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 165
- Source count
- 165
- Agreement rate
- 0.672727
- Recorded readings
7±1 hour
- Numeric value
- 7
- Unit
- hours
- Source records
- 111
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 111 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0a688786-879b-4e27-a46a-5c86bbfa1292 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7±1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c82313cb-744f-45ef-b74c-1bdd055b2193 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1d67cb3c-1173-4dce-a79b-a3c36934ab2e (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d307850-0ed5-4f32-ac62-0e1e2fe27a7a (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e662bf5b-c81c-4bcd-ba2e-552df95ca6f9 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c3b62114-a590-f4db-e053-2995a90a9d30 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7±1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b1e988f7-8bbe-4ef4-8b0a-b2a8af8a482b (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:591dd9f1-3681-4b2f-b096-7536826e3648 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dfc218c5-672a-420a-b59e-2e0b054e99ad (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7±1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51b66893-f7d6-8f9d-e063-6294a90a8e9b (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fc4c72e2-9cba-88d9-e053-6394a90a0426 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7±1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:43df4156-0958-e496-e063-6294a90a5329 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0348fec4-d919-4307-ac90-35360819bc00 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6913c611-4994-4501-8ed9-45161f90373e (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6bdbc193-d86b-4bd5-8e88-4ea964d2cdde (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1f3c04d9-cccb-06a3-a0f3-f7c9228ee743 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e31c6830-4647-4481-b4f1-494a52c48b1b (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c4b27429-50a3-467c-a5ff-7e49a01a1088 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a3c57d82-511c-4c7d-84ff-f791f931f576 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:53843871-23e3-974e-e063-6394a90a8042 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:551626eb-3282-e439-e063-6294a90a8314 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1c4450a1-6c05-4b45-a733-c19b4e861970 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c4a3018a-3cd8-4e07-a840-099ceae01c91 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d818ef84-9b3e-434b-92d9-910cfa8af7da (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ed8e88d0-993e-4683-bdcf-31578130d3df (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c2177034-e164-453c-be02-1cf91ce27a07 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:08e1bfea-7f3f-42d9-823d-f75080e664ff (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0a987d59-560f-4650-96ec-31aec81953b5 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bc12f0b0-e05c-48e4-ad08-0ff14a818a64 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b9597cd5-5745-494a-bd72-93071ed221da (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7±1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3884cb76-822b-400d-9b24-49c286c9b6f7 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9e3171c9-70e2-4725-8aca-c7f83773940d (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7696961e-dfff-422a-b72f-e31ceeac10af (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:423d2185-0931-4414-8864-7594000809ee (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:01aef7f7-6092-4e39-8451-dc02d8db9254 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9dca1330-52ca-47a4-a134-ec55c9d5786d (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2471ee03-d747-4113-86d0-1aa93c8f3eba (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f65ec19d-b90e-452e-b761-c68b1cf2c892 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8b74b8bc-d95c-4471-8f74-c3117243bf89 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8c16bc7b-672c-420a-a457-350060533375 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e72a7410-13fd-40e4-befb-052d0455e038 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:513f422f-1637-5f41-e063-6294a90ab548 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:df661166-325d-4071-9bc1-f7bf992996d2 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f924d55d-d7ec-4448-b54e-3a7eaf5a1cab (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a05bbfa4-c34f-4134-8207-db79e4c70445 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:be651c31-383f-11e4-916c-0800200c9a66 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5037a86a-21f2-d793-e063-6394a90a2cb5 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:30f43d3b-c944-4f25-b5d3-009294944962 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dfb7c640-623e-43d1-8ee8-479dccd53d0a (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8a8472dc-b97e-445d-bf51-b6e618cae1b6 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fc8bf57e-8aa2-4d3c-856d-b19de65e3ba0 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:792db8dc-177b-4864-8600-12823819082d (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7±1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5eb7bea5-c95f-4a38-a5bb-c20d1549c797 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6e31e766-6504-4f20-8831-1953363cace0 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:671a1ae1-f672-48da-8a69-94c147472003 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:58ed7049-44c6-4f97-9174-c0e1504586a6 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c3daf220-9741-41c4-b89d-e06cee36dac6 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dd713e60-478c-43cd-b680-ff594a0b3864 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b4781ec4-43ad-4052-9a6a-b24fda119b32 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a91defd2-486b-4995-ba4c-640525ab575d (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ae405796-1eca-4890-bcb2-e1b07654a24d (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7±1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bc8b413f-2f07-4e6a-bb8e-a1f2119ae1cf (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7±1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5c4877cc-52bc-4f98-a995-0aa9439da742 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0bc8468f-832c-4e71-95a2-db464d4d54bc (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:db423b93-d7c2-4cf2-829b-24b657f27f93 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:45a07f44-078d-0513-e063-6394a90a1629 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3ca9df05-a506-4ec8-a4fe-320f1219ab21 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57f09129-7151-4a75-9d73-9dd32f74ba43 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3756f052-919c-4817-a56e-1091fd514d9d (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ba18ead0-69d7-453a-badc-cd6ad376d18e (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:90e01877-abcb-4697-a7ed-9afe5ee77050 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1c26c0ad-9d37-45c5-9091-849509f4fc01 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bb6e1c75-66eb-4d18-af70-9b51fb67c4d6 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:56fed03f-38c3-4273-8fd7-522bc508bf36 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:567f09e6-ccd5-4688-a22b-0bc66a5fe31e (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7±1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:34af3602-0188-4d2e-904b-2e40000bb45c (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:adbcb0f7-0421-47e2-854e-e1cfefb6386f (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7±1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b738377c-035e-4b2e-9909-0a8fe07aa0fb (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d596153-c49b-273f-e063-6294a90ac663 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:45a03a43-04db-9138-e063-6394a90a12fa (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:28c0e61e-1af9-410a-9fa9-b71bf99a776b (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ±1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1d71212b-ac97-4a61-8192-8e8303540019 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c12d8af3-39a8-4690-8d47-43dec70b7579 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:031a32e1-675a-4efe-a66b-40beb4fe5101 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1ec4c05d-7fba-4c02-a3bf-4343a8a421d5 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:483a42b9-c8f3-4f8b-98be-fcac5ab23c7c (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3be7c30b-f35d-4dde-8bf8-24f67bd70865 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:deca634a-651e-4c70-9fc3-b0087b537b0a (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:23073db5-3fc4-4051-a22d-e49a63e42647 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5517b148-1eff-6421-e063-6394a90a9498 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:49117cee-a96c-4593-91a7-8a133e3f0939 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dd175fa3-1d7a-4542-affd-988ac5bba1db (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:61eb57a9-5df2-4426-9f0c-a75e2f356b11 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf412e94-ca36-4da9-83d7-fb0f1323cf21 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:24f815ef-58e6-42b9-8137-adcd6c382aa6 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52fa0eec-3dd9-59ca-e063-6394a90a9791 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:74ccc9f1-b957-4b1b-9464-1b5e3318c916 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:266d4ead-fda2-f030-e063-6394a90a68e2 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a1b28234-1f7c-40bf-80a7-6cc98b3839fe (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:419b3dba-ae21-4268-ac8b-342aaa609554 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7±1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:02e237ff-a3e0-40fe-a3d0-9d8802855c71 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e1ebd960-79a4-4632-b727-4e9811824113 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ee03507b-cb35-4fe9-ae7b-85ea89f876f0 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5cb4a1db-f32d-44af-8985-0a94ca506468 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f7c96494-6cb2-4d00-8c5a-5bec4e0c70c0 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d7932a2c-a3b7-46df-a306-1f17716160a0 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6ab24168-058d-496e-9023-da8ee6353eb3 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:63b36274-89f0-42d8-9f09-f9e78e179af4 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7±1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:94d042f7-93b9-43bd-9ace-cfc61903b4d7 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c4b2da6a-ed50-4a54-90bd-32f76b178736 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e1b14939-7262-40dc-a334-2b3b72c88d47 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
6 to 8 hours
- Numeric value
- 6
- Unit
- hours
- Source records
- 32
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 32 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1d9abcce-8ef7-422b-bf4b-5835bf4dbb34 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Plasma half-life of levetiracetam across studies is approximately 6 to 8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0a9234b7-46b1-8e6c-a992-90f86cfb6e00 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Plasma half-life of levetiracetam across studies is approximately 6 to 8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5e5b0ed3-b104-45a7-bb3e-ee56febb46e8 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Plasma half-life of levetiracetam across studies is approximately 6-8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:da858849-1d18-4d38-b53d-d4dd1cd8fabc (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Plasma half-life of levetiracetam across studies is approximately 6 to 8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4f8ffd81-f814-f288-e063-6394a90a5eb5 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Plasma half-life of levetiracetam across studies is approximately 6-8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aa883d9c-c6cd-44ab-a1de-058985e4f97f (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Plasma half-life of levetiracetam across studies is approximately 6 to 8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:70e52e89-3844-4cd9-a406-b29e9520a12c (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Plasma half-life of levetiracetam across studies is approximately 6-8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6fb1e4d3-520c-44f1-a09d-d7b779e4edfd (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Plasma half-life of levetiracetam across studies is approximately 6-8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:72f7ddd9-1b2c-4e26-8060-20e10c1c5d1c (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Plasma half-life of levetiracetam across studies is approximately 6-8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ed1b74a8-2a9b-4315-b051-673c7941cb13 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Plasma half-life of levetiracetam across studies is approximately 6 to 8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ee014183-a857-457b-9573-0cc168e560f3 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Plasma halflife of levetiracetam across studies is approximately 6-8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:be8ec971-c4f1-3e53-77e1-8337d9d506eb (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Plasma half-life of levetiracetam across studies is approximately 6 to 8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ad32ec2f-b4e0-4811-8ea1-7a4abdd5c0a6 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Plasma half-life of levetiracetam across studies is approximately 6 to 8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3e43c17f-7e7e-4ccd-b321-1dd5e62cdafd (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Plasma half-life of levetiracetam across studies is approximately 6 to 8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cc4a06f1-6509-4650-b20c-259a39353733 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Plasma half-life of levetiracetam across studies is approximately 6 to 8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8d767545-1eb9-45a5-bd16-e8a66e628fea (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Plasma half-life of levetiracetam across studies is approximately 6-8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e86dc508-4d22-493b-bdf1-408b6484d3f1 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Plasma half-life of levetiracetam across studies is approximately 6 to 8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d2de9565-0c0b-4957-bafa-1a286103709e (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Plasma half-life of levetiracetam across studies is approximately 6 to 8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cfe618ae-f7de-43d8-a754-3ce0a08c48ee (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Plasma half-life of levetiracetam across studies is approximately 6-8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:47cfe577-b4cb-d35e-e063-6394a90ad8c4 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Plasma half-life of levetiracetam across studies is approximately 6-8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:65a76fcb-31a8-4c5a-9ffe-5393fc4dac34 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Plasma half-life of levetiracetam across studies is approximately 6-8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7be45c40-8d75-4c40-97a4-95067129bc2a (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Plasma half-life of levetiracetam across studies is approximately 6 to 8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c6d5784d-abf9-45fe-ac5a-d5c53bd50f7e (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Plasma half-life of levetiracetam across studies is approximately 6-8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:097e5606-dd5e-4518-ab97-f71f68786444 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Plasma half-life of levetiracetam across studies is approximately 6-8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cc41696c-9cf0-4410-bacc-09132ee805ce (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Plasma half-life of levetiracetam across studies is approximately 6 to 8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:62f3d1c8-ca5b-4760-9fc9-41e4fb4cc926 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Plasma half-life of levetiracetam across studies is approximately 6-8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1591c690-f4ed-44b7-a9d0-bff1fbb4bfef (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Plasma half-life of levetiracetam across studies is approximately 6-8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1e3cfafe-5784-4ec6-91dc-cd74b01d0bb4 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Plasma half-life of levetiracetam across studies is approximately 6 to 8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:484e8d8f-be40-46f8-a509-d1bbdbbd2981 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Plasma half-life of levetiracetam across studies is approximately 6-8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f1935bc8-30ce-4b51-8a4c-0f12ce9000a6 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Plasma half-life of levetiracetam across studies is approximately 6 to 8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6951de41-4a16-4cca-8039-44fc81407081 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Plasma half-life of levetiracetam across studies is approximately 6 to 8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:35bb1e5f-d5cd-4e7f-a056-48c0cf9ebd76 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Plasma half-life of levetiracetam across studies is approximately 6 to 8 hours.
7 hours
- Numeric value
- 7
- Unit
- hours
- Source records
- 19
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 19 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9bdef24b-c50e-4e6a-8650-59d78009f472 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Plasma half-life of extended-release levetiracetam is approximately 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c508a392-0603-477d-8a45-3ec550371111 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Plasma half-life of extended-release levetiracetam is approximately 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:30a4626d-74f3-6385-e063-6394a90a2950 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 hours ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:402b488c-1733-4bf7-a7a8-b60805b022c9 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Plasma half-life of extended-release levetiracetam is approximately 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:17969eda-4c85-40a0-9a94-7e4675adf910 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Plasma half-life of extended-release levetiracetam is approximately 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5dde1889-a217-4493-9a71-9fd39ed04630 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Plasma half-life of extended-release levetiracetam is approximately 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1d75b15e-881c-a00f-e063-6394a90a4138 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 hours ± 1 hour and is unaffected by either dose or repeated administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bc8644ed-3320-47b5-adf3-8b972bea8abd (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Plasma half-life of extended-release levetiracetam is approximately 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d57f22f-fecc-466e-a444-87708c7c2f80 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Plasma half-life of extended-release levetiracetam is approximately 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a0ad8200-70c9-4f4f-86c5-4a8c6c9f0223 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Plasma half-life of extended-release levetiracetam is approximately 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3e32f341-9926-47a3-a942-d8b9bfa7a55b (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Plasma half-life of extended-release levetiracetam is approximately 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2919e43b-69a8-434c-a2d2-1f3ecd7554c0 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Plasma half-life of extended-release levetiracetam is approximately 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1a31134d-6b63-4d14-8445-0ed132e6c88d (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Plasma half-life of extended-release levetiracetam is approximately 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57b9dccb-6ee6-4e89-ab26-4c478e2df2b5 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Plasma half-life of extended-release levetiracetam is approximately 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cac83d47-88a2-4447-a0c0-90b44ffda0ac (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Plasma half-life of extended-release levetiracetam is approximately 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7cb669d7-d1aa-43b3-a322-0a2eaa13c656 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Plasma half-life of extended-release levetiracetam is approximately 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:abc9fada-c5c2-4e07-fb8a-4d1518f7657e (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Plasma half-life of extended-release levetiracetam is approximately 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:18648f51-a37c-41e1-b451-123bc0cf5446 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Plasma half-life of extended-release levetiracetam is approximately 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ace53552-d616-45e8-9f99-2f0041d0b430 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Plasma half-life of extended-release levetiracetam is approximately 7 hours.
6 hours
- Numeric value
- 6
- Unit
- hours
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3d88adda-9580-44bf-b75c-d615c973c1e1 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Plasma half-life of levetiracetam across studies is approximately 6 hours to 8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8e381590-1147-46f3-9cbd-dc9716013444 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Plasma half-life of levetiracetam across studies is approximately 6 hours to 8 hours.
1 hour
- Numeric value
- 1
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e77162ff-0ff9-45ca-95fc-da6ea24ce5a2 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Elimination Levetiracetam plasma half-life in adults is 7 + 1 hour and is unaffected by either dose or repeated administration.
Projected row 842
- Medicine slug
- levetiracetam
- Compared field
- tMax
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 165
- Source count
- 149
- Agreement rate
- 0.885906
- Recorded readings
1 hour
- Numeric value
- 1
- Unit
- hours
- Source records
- 132
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 132 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0a688786-879b-4e27-a46a-5c86bbfa1292 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a Tmax of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c82313cb-744f-45ef-b74c-1bdd055b2193 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:30a4626d-74f3-6385-e063-6394a90a2950 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1d67cb3c-1173-4dce-a79b-a3c36934ab2e (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d307850-0ed5-4f32-ac62-0e1e2fe27a7a (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e662bf5b-c81c-4bcd-ba2e-552df95ca6f9 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c3b62114-a590-f4db-e053-2995a90a9d30 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a Tmax of about 1 hour and a t1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b1e988f7-8bbe-4ef4-8b0a-b2a8af8a482b (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:591dd9f1-3681-4b2f-b096-7536826e3648 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dfc218c5-672a-420a-b59e-2e0b054e99ad (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51b66893-f7d6-8f9d-e063-6294a90a8e9b (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t ½ of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4f8ffd81-f814-f288-e063-6394a90a5eb5 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses, with a T max of about 1 hour and a t 1/2 of 5 hours across all dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fc4c72e2-9cba-88d9-e053-6394a90a0426 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:43df4156-0958-e496-e063-6294a90a5329 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0348fec4-d919-4307-ac90-35360819bc00 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6913c611-4994-4501-8ed9-45161f90373e (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6bdbc193-d86b-4bd5-8e88-4ea964d2cdde (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1f3c04d9-cccb-06a3-a0f3-f7c9228ee743 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e31c6830-4647-4481-b4f1-494a52c48b1b (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6fb1e4d3-520c-44f1-a09d-d7b779e4edfd (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses, with a T max of about 1 hour and a t 1/2 of 5 hours across all dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c4b27429-50a3-467c-a5ff-7e49a01a1088 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:72f7ddd9-1b2c-4e26-8060-20e10c1c5d1c (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses, with a T max of about 1 hour and a t 1/2 of 5 hours across all dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a3c57d82-511c-4c7d-84ff-f791f931f576 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:53843871-23e3-974e-e063-6394a90a8042 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t ½ of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:551626eb-3282-e439-e063-6294a90a8314 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t ½ of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1c4450a1-6c05-4b45-a733-c19b4e861970 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c4a3018a-3cd8-4e07-a840-099ceae01c91 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d818ef84-9b3e-434b-92d9-910cfa8af7da (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ed8e88d0-993e-4683-bdcf-31578130d3df (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c2177034-e164-453c-be02-1cf91ce27a07 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:08e1bfea-7f3f-42d9-823d-f75080e664ff (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0a987d59-560f-4650-96ec-31aec81953b5 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bc12f0b0-e05c-48e4-ad08-0ff14a818a64 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b9597cd5-5745-494a-bd72-93071ed221da (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3884cb76-822b-400d-9b24-49c286c9b6f7 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9e3171c9-70e2-4725-8aca-c7f83773940d (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7696961e-dfff-422a-b72f-e31ceeac10af (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:423d2185-0931-4414-8864-7594000809ee (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:01aef7f7-6092-4e39-8451-dc02d8db9254 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9dca1330-52ca-47a4-a134-ec55c9d5786d (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2471ee03-d747-4113-86d0-1aa93c8f3eba (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f65ec19d-b90e-452e-b761-c68b1cf2c892 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8b74b8bc-d95c-4471-8f74-c3117243bf89 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t ½ of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8c16bc7b-672c-420a-a457-350060533375 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e77162ff-0ff9-45ca-95fc-da6ea24ce5a2 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a Tmax of about 1 hour and a t1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e72a7410-13fd-40e4-befb-052d0455e038 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1d75b15e-881c-a00f-e063-6394a90a4138 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:513f422f-1637-5f41-e063-6294a90ab548 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:df661166-325d-4071-9bc1-f7bf992996d2 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f924d55d-d7ec-4448-b54e-3a7eaf5a1cab (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a05bbfa4-c34f-4134-8207-db79e4c70445 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:be651c31-383f-11e4-916c-0800200c9a66 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a t max of about 1 hour and a t ½ of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5037a86a-21f2-d793-e063-6394a90a2cb5 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t ½ of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:30f43d3b-c944-4f25-b5d3-009294944962 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3e43c17f-7e7e-4ccd-b321-1dd5e62cdafd (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses, with a T max of about 1 hour and a t 1/2 of 5 hours across all dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dfb7c640-623e-43d1-8ee8-479dccd53d0a (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cc4a06f1-6509-4650-b20c-259a39353733 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses, with a T max of about 1 hour and a t 1/2 of 5 hours across all dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8a8472dc-b97e-445d-bf51-b6e618cae1b6 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fc8bf57e-8aa2-4d3c-856d-b19de65e3ba0 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:792db8dc-177b-4864-8600-12823819082d (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5eb7bea5-c95f-4a38-a5bb-c20d1549c797 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6e31e766-6504-4f20-8831-1953363cace0 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:671a1ae1-f672-48da-8a69-94c147472003 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:58ed7049-44c6-4f97-9174-c0e1504586a6 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c3daf220-9741-41c4-b89d-e06cee36dac6 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dd713e60-478c-43cd-b680-ff594a0b3864 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b4781ec4-43ad-4052-9a6a-b24fda119b32 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a91defd2-486b-4995-ba4c-640525ab575d (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ae405796-1eca-4890-bcb2-e1b07654a24d (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8d767545-1eb9-45a5-bd16-e8a66e628fea (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses, with a Tmax of about 1 hour and a t1/2 of 5 hours across all dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bc8b413f-2f07-4e6a-bb8e-a1f2119ae1cf (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e86dc508-4d22-493b-bdf1-408b6484d3f1 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses, with a T max of about 1 hour and a t 1/2 of 5 hours across all dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5c4877cc-52bc-4f98-a995-0aa9439da742 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite, 1-ethyl-2-oxo-pyrolidine acetic acid, in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0bc8468f-832c-4e71-95a2-db464d4d54bc (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:db423b93-d7c2-4cf2-829b-24b657f27f93 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:45a07f44-078d-0513-e063-6394a90a1629 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3ca9df05-a506-4ec8-a4fe-320f1219ab21 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57f09129-7151-4a75-9d73-9dd32f74ba43 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3756f052-919c-4817-a56e-1091fd514d9d (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ba18ead0-69d7-453a-badc-cd6ad376d18e (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:90e01877-abcb-4697-a7ed-9afe5ee77050 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1c26c0ad-9d37-45c5-9091-849509f4fc01 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bb6e1c75-66eb-4d18-af70-9b51fb67c4d6 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:56fed03f-38c3-4273-8fd7-522bc508bf36 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:567f09e6-ccd5-4688-a22b-0bc66a5fe31e (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:34af3602-0188-4d2e-904b-2e40000bb45c (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:adbcb0f7-0421-47e2-854e-e1cfefb6386f (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b738377c-035e-4b2e-9909-0a8fe07aa0fb (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d596153-c49b-273f-e063-6294a90ac663 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cfe618ae-f7de-43d8-a754-3ce0a08c48ee (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses, with a T max of about 1 hour and a t 1/2 of 5 hours across all dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:45a03a43-04db-9138-e063-6394a90a12fa (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:28c0e61e-1af9-410a-9fa9-b71bf99a776b (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a Tmax of about 1 hour and a t1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:47cfe577-b4cb-d35e-e063-6394a90ad8c4 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses, with a T max of about 1 hour and a t 1/2 of 5 hours across all dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:65a76fcb-31a8-4c5a-9ffe-5393fc4dac34 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses, with a Tmax of about 1 hour and a t1/2 of 5 hours across all dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1d71212b-ac97-4a61-8192-8e8303540019 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c12d8af3-39a8-4690-8d47-43dec70b7579 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7be45c40-8d75-4c40-97a4-95067129bc2a (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses, with a T max of about 1 hour and a t 1/2 of 5 hours across all dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:031a32e1-675a-4efe-a66b-40beb4fe5101 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1ec4c05d-7fba-4c02-a3bf-4343a8a421d5 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:483a42b9-c8f3-4f8b-98be-fcac5ab23c7c (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3be7c30b-f35d-4dde-8bf8-24f67bd70865 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c6d5784d-abf9-45fe-ac5a-d5c53bd50f7e (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses, with a T max of about 1 hour and a t 1/2 of 5 hours across all dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:097e5606-dd5e-4518-ab97-f71f68786444 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses, with a T max of about 1 hour and a t 1/2 of 5 hours across all dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:deca634a-651e-4c70-9fc3-b0087b537b0a (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:23073db5-3fc4-4051-a22d-e49a63e42647 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5517b148-1eff-6421-e063-6394a90a9498 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T maxof about 1 hour and a t 1/2of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cc41696c-9cf0-4410-bacc-09132ee805ce (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses, with a T max of about 1 hour and a t 1/2 of 5 hours across all dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:49117cee-a96c-4593-91a7-8a133e3f0939 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1591c690-f4ed-44b7-a9d0-bff1fbb4bfef (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses, with a T max of about 1 hour and a t 1/2 of 5 hours across all dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dd175fa3-1d7a-4542-affd-988ac5bba1db (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a t max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:61eb57a9-5df2-4426-9f0c-a75e2f356b11 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf412e94-ca36-4da9-83d7-fb0f1323cf21 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t ½ of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:24f815ef-58e6-42b9-8137-adcd6c382aa6 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52fa0eec-3dd9-59ca-e063-6394a90a9791 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T maxof about 1 hour and a t 1/2of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:74ccc9f1-b957-4b1b-9464-1b5e3318c916 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:266d4ead-fda2-f030-e063-6394a90a68e2 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8e381590-1147-46f3-9cbd-dc9716013444 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses, with a T max of about 1 hour and a t 1/2 of 5 hours across all dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a1b28234-1f7c-40bf-80a7-6cc98b3839fe (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1e3cfafe-5784-4ec6-91dc-cd74b01d0bb4 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses, with a T max of about 1 hour and a t 1/2 of 5 hours across all dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:419b3dba-ae21-4268-ac8b-342aaa609554 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:02e237ff-a3e0-40fe-a3d0-9d8802855c71 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e1ebd960-79a4-4632-b727-4e9811824113 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:484e8d8f-be40-46f8-a509-d1bbdbbd2981 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses, with a Tmax of about 1 hour and a t1/2 of 5 hours across all dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ee03507b-cb35-4fe9-ae7b-85ea89f876f0 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5cb4a1db-f32d-44af-8985-0a94ca506468 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f7c96494-6cb2-4d00-8c5a-5bec4e0c70c0 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a Tmax of about 1 hour and a t1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d7932a2c-a3b7-46df-a306-1f17716160a0 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite, 1-ethyl-2-oxo-pyrolidine acetic acid, in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6ab24168-058d-496e-9023-da8ee6353eb3 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:63b36274-89f0-42d8-9f09-f9e78e179af4 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:94d042f7-93b9-43bd-9ace-cfc61903b4d7 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c4b2da6a-ed50-4a54-90bd-32f76b178736 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e1b14939-7262-40dc-a334-2b3b72c88d47 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
4 hours
- Numeric value
- 4
- Unit
- hours
- Source records
- 17
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 17 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9bdef24b-c50e-4e6a-8650-59d78009f472 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Absorption and Distribution Extended-release levetiracetam peak plasma concentrations occur in about 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c508a392-0603-477d-8a45-3ec550371111 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Absorption and Distribution Extended-release levetiracetam peak plasma concentrations occur in about 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:402b488c-1733-4bf7-a7a8-b60805b022c9 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Absorption and Distribution Extended-release levetiracetam peak plasma concentrations occur in about 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:17969eda-4c85-40a0-9a94-7e4675adf910 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Absorption and Distribution Extended-release levetiracetam peak plasma concentrations occur in about 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5dde1889-a217-4493-9a71-9fd39ed04630 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Absorption and Distribution Extended-release levetiracetam peak plasma concentrations occur in about 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bc8644ed-3320-47b5-adf3-8b972bea8abd (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Absorption and Distribution Extended-release levetiracetam peak plasma concentrations occur in about 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d57f22f-fecc-466e-a444-87708c7c2f80 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Absorption and Distribution Extended-release levetiracetam peak plasma concentrations occur in about 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a0ad8200-70c9-4f4f-86c5-4a8c6c9f0223 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Absorption and Distribution Extended-release levetiracetam peak plasma concentrations occur in about 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3e32f341-9926-47a3-a942-d8b9bfa7a55b (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Absorption and Distribution Extended-release levetiracetam peak plasma concentrations occur in about 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2919e43b-69a8-434c-a2d2-1f3ecd7554c0 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Absorption and Distribution Extended-release levetiracetam peak plasma concentrations occur in about 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1a31134d-6b63-4d14-8445-0ed132e6c88d (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Absorption and Distribution Extended-release levetiracetam peak plasma concentrations occur in about 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57b9dccb-6ee6-4e89-ab26-4c478e2df2b5 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Absorption and Distribution Extended-release levetiracetam peak plasma concentrations occur in about 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cac83d47-88a2-4447-a0c0-90b44ffda0ac (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Absorption and Distribution Extended-release levetiracetam peak plasma concentrations occur in about 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7cb669d7-d1aa-43b3-a322-0a2eaa13c656 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Absorption and Distribution Extended-release levetiracetam peak plasma concentrations occur in about 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:abc9fada-c5c2-4e07-fb8a-4d1518f7657e (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Absorption and Distribution Extended-release levetiracetam peak plasma concentrations occur in about 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:18648f51-a37c-41e1-b451-123bc0cf5446 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Absorption and Distribution Extended-release levetiracetam peak plasma concentrations occur in about 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ace53552-d616-45e8-9f99-2f0041d0b430 (opens source in a new tab)
Levetiracetam label
Version not recorded · Effective date not recorded
Absorption and Distribution Extended-release levetiracetam peak plasma concentrations occur in about 4 hours.
Projected row 843
- Medicine slug
- levocarnitine
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 14
- Source count
- 12
- Agreement rate
- 1
- Recorded readings
3.3 hours
- Numeric value
- 3.3
- Unit
- hours
- Source records
- 12
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 12 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:75b43fb1-4486-48a0-b571-7754dce350a3 (opens source in a new tab)
Levocarnitine label
Version not recorded · Effective date not recorded
Following 4 days of dosing with 6 tablets of levocarnitine 330 mg b.i.d. or 2 g of levocarnitine oral solution b.i.d., the maximum plasma concentration (C max ) was about 80 µmol/L and the time to maximum plasma concentration (T max ) occurred at 3.3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cf801cc4-775e-433d-9d32-e5d9a98981d3 (opens source in a new tab)
Levocarnitine label
Version not recorded · Effective date not recorded
Following 4 days of dosing with 6 tablets of CARNITOR ® 330 mg b.i.d. or 2 g of CARNITOR ® oral solution b.i.d., the maximum plasma concentration (C max ) was about 80 µmol/L and the time to maximum plasma concentration (T max ) occurred at 3.3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1f38ab0d-ef89-4e92-990f-9da190057e17 (opens source in a new tab)
Levocarnitine label
Version not recorded · Effective date not recorded
Following 4 days of dosing with 6 tablets of levocarnitine 330 mg b.i.d. or 2 g of levocarnitine oral solution b.i.d., the maximum plasma concentration (C max ) was about 80 µmol/L and the time to maximum plasma concentration (T max ) occurred at 3.3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dd904490-83f3-4cd3-bb6f-68e28509b4b6 (opens source in a new tab)
Levocarnitine label
Version not recorded · Effective date not recorded
Following 4 days of dosing with 6 tablets of CARNITOR ® 330 mg b.i.d. or 2 g of CARNITOR ® oral solution b.i.d., the maximum plasma concentration (C max ) was about 80 µmol/L and the time to maximum plasma concentration (T max ) occurred at 3.3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8f255df8-8a1f-4b4f-ae8c-2c80532ce8d4 (opens source in a new tab)
Levocarnitine label
Version not recorded · Effective date not recorded
Following 4 days of dosing with 6 tablets of levocarnitine 330 mg b.i.d. or 2 g of levocarnitine oral solution b.i.d., the maximum plasma concentration (C max ) was about 80 µmol/L and the time to maximum plasma concentration (T max ) occurred at 3.3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:05ab18c1-fb01-48fa-8f05-0200bb8a5edf (opens source in a new tab)
Levocarnitine label
Version not recorded · Effective date not recorded
Following 4 days of dosing with 6 tablets of levocarnitine 330 mg b.i.d. or 2 g of levocarnitine oral solution b.i.d., the maximum plasma concentration (C max ) was about 80 µmol/L and the time to maximum plasma concentration (T max ) occurred at 3.3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ada35959-e317-4161-ae79-3475096c679f (opens source in a new tab)
Levocarnitine label
Version not recorded · Effective date not recorded
Following 4 days of dosing with 6 tablets of levocarnitine 330 mg b.i.d. or 2 g of levocarnitine oral solution b.i.d., the maximum plasma concentration (Cmax) was about 80 µmol/L and the time to maximum plasma concentration (Tmax) occurred at 3.3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cc4da2c3-f939-444d-9b5b-a57b6051c190 (opens source in a new tab)
Levocarnitine label
Version not recorded · Effective date not recorded
Following 4 days of dosing with 6 tablets of levocarnitine 330 mg twice daily or 2 g of levocarnitine oral solution twice daily, the maximum plasma concentration (C max ) was about 80 μmol/L and the time to maximum plasma concentration (T max ) occurred at 3.3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d2133bc3-9c15-48bd-8b16-b8995a6a14cd (opens source in a new tab)
Levocarnitine label
Version not recorded · Effective date not recorded
Following 4 days of dosing with 6 tablets of CARNITOR ® 330 mg b.i.d. or 2 g of CARNITOR ® oral solution b.i.d., the maximum plasma concentration (C max ) was about 80 µmol/L and the time to maximum plasma concentration (T max ) occurred at 3.3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:79b6182c-ead5-4fdd-bafa-1afbc7a77906 (opens source in a new tab)
Levocarnitine label
Version not recorded · Effective date not recorded
Following 4 days of dosing with 6 tablets of Levocarnitine 330 mg b.i.d. or 2 g of Levocarnitine oral solution b.i.d., the maximum plasma concentration (Cmax) was about 80 µmol/L and the time to maximum plasma concentration (Tmax) occurred at 3.3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0f749812-8f02-4eeb-91d9-5dd6fc9fa159 (opens source in a new tab)
Levocarnitine label
Version not recorded · Effective date not recorded
Following 4 days of dosing with 6 tablets of levocarnitine 330 mg b.i.d. or 2 g of levocarnitine oral solution b.i.d., the maximum plasma concentration (C max ) was about 80 μmol/L and the time to maximum plasma concentration (T max ) occurred at 3.3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b2cbc620-59fd-47b6-9e4b-7e3e31533a1c (opens source in a new tab)
Levocarnitine label
Version not recorded · Effective date not recorded
Following 4 days of dosing with 6 tablets of CARNITOR ® 330 mg b.i.d. or 2 g of CARNITOR ® oral solution b.i.d., the maximum plasma concentration (C max ) was about 80 µmol/L and the time to maximum plasma concentration (T max ) occurred at 3.3 hours.
Projected row 844
- Medicine slug
- levodopa
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
70%
- Numeric value
- 70
- Unit
- %
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a906f8e1-6e1c-480a-8276-c01bc65dd3be (opens source in a new tab)
Levodopa label
Version not recorded · Effective date not recorded
In fasted healthy volunteers the bioavailability of levodopa from INBRIJA was approximately 70% relative to immediate-release oral levodopa tablets.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:077c0f39-a3a2-4b2b-a184-09131889dcfb (opens source in a new tab)
Levodopa label
Version not recorded · Effective date not recorded
In fasted healthy volunteers the bioavailability of levodopa from INBRIJA was approximately 70% relative to immediate-release oral levodopa tablets.
Projected row 845
- Medicine slug
- levodopa
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
0.5 hours
- Numeric value
- 0.5
- Unit
- hours
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a906f8e1-6e1c-480a-8276-c01bc65dd3be (opens source in a new tab)
Levodopa label
Version not recorded · Effective date not recorded
Absorption After a single dose of INBRIJA 84 mg (two 42 mg capsules), the median T max for plasma levodopa was approximately 0.5 hours (range 0.17–2.00 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:077c0f39-a3a2-4b2b-a184-09131889dcfb (opens source in a new tab)
Levodopa label
Version not recorded · Effective date not recorded
Absorption After a single dose of INBRIJA 84 mg (two 42 mg capsules), the median T max for plasma levodopa was approximately 0.5 hours (range 0.17–2.00 hours).
Projected row 846
- Medicine slug
- levodopa
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
168 L
- Numeric value
- 168
- Unit
- L
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a906f8e1-6e1c-480a-8276-c01bc65dd3be (opens source in a new tab)
Levodopa label
Version not recorded · Effective date not recorded
Distribution Apparent volume of distribution (Vz/F) was 168 L for INBRIJA 84 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:077c0f39-a3a2-4b2b-a184-09131889dcfb (opens source in a new tab)
Levodopa label
Version not recorded · Effective date not recorded
Distribution Apparent volume of distribution (Vz/F) was 168 L for INBRIJA 84 mg.
Projected row 847
- Medicine slug
- levofloxacin
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 76
- Source count
- 74
- Agreement rate
- 1
- Recorded readings
6 to 8 hours
- Numeric value
- 6
- Unit
- hours
- Source records
- 74
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 74 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cbd5153f-fada-4682-b858-dc3b6e3173cc (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:af4b7333-4f77-4ec9-e053-2a95a90a16d2 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bfe280be-0789-69fa-e053-2a95a90a0e13 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:64141d0d-0347-470f-a427-9925a2eb357e (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b8defac4-9deb-433b-928e-0ef4ee0123a2 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:70c87464-1806-480a-8ebd-3f02987ff436 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c6027cde-b9fe-e593-e053-2995a90ac2c1 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dabedb15-5b55-3853-e053-2995a90aa44e (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:54a02488-586d-4c4e-8a35-68a067bdd6e3 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4a405103-41e8-6a1f-e054-00144ff8d46c (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ba69722b-d7f2-4519-8a63-9ee91294c499 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8423b021-e09c-4f1c-e053-2991aa0afef6 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4d400bf9-988f-42ec-93f1-e71a93a324b2 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f2f090c2-3ee1-7689-e053-2995a90abe38 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9020cdeb-65fe-458f-bbbd-69265a49906e (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5261da15-1b6c-fbe2-e063-6394a90ad85e (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:699fbdb8-a6fd-476a-9b80-08197d869534 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e680c759-16c5-4532-9c9c-f42c8c3df74a (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:95149cfb-1a71-42b7-b50d-9a2e94334339 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:171ab6c6-8eb5-4716-926f-cee52b7d0968 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:05d179f5-b200-8597-e063-6394a90a10cc (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:264a3f71-f23e-45e3-926a-421bcccf4e3d (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:070375be-3b67-4299-ae8f-4a7b157ac16f (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5c6c117c-9d91-48f4-9aaa-ee70b99218c2 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:59f387a4-4dfa-ba71-e063-6294a90a340c (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a894e40b-77e4-439b-b0f8-9a5cc7a1dd90 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b1a4aabb-42af-4133-8e82-0c7ec8fa79c3 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:857f256c-88ac-4f73-9815-c2724edf2f1e (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eb30fafa-bbb9-458f-89df-ae610fa6aa96 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:804ec547-5b89-4fd0-89b3-7445543e563e (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bdc8b2cc-a914-4613-ac7c-e8dfe91dea13 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:afd5cb35-4232-f8b1-e053-2a95a90a8c5b (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2a4e97e0-0709-411b-92e8-6f7d669412e4 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:710c0c10-89a5-4954-8f74-acc187c5cf0f (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bcad1dad-53aa-43dd-90f3-cc17cc9598d5 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f33140d5-59ad-3379-e053-2995a90ae286 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:30958610-3803-45e6-aa3c-d256decbe6e4 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d98cf024-51fa-45a1-b247-da55aba88ca0 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ac4001ca-882f-4d9b-a570-c1b9d7fd6830 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5a1534af-aa1c-4f1d-ba9f-9415b14e1af2 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:16d51c1c-4144-4be7-9356-98fcee621ecd (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f780bb91-483a-d1a6-e053-6294a90ab74b (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:44f31105-5fc9-43d4-e063-6294a90a510f (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2a8676a9-247f-4fdb-b644-e9785d98771f (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9f944b63-9b60-437a-ba57-d14d7976bc32 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4f40d5fa-ebcc-516c-e054-00144ff8d46c (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b7a614b0-f604-48e1-9919-21da8f939d93 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:72cb9372-e9f8-3ca1-e053-2a91aa0ad820 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b43e9b51-568c-4d84-bbd1-d237120056c4 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:814450ae-439e-4a5d-8c60-9b21b6f14be5 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:427a2077-5dbb-3c5e-e063-6294a90a0839 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b9dc8bf3-97d9-4d1c-9a68-3ae553acdada (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1538ec66-f385-401e-8cfb-d794691e7176 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f23c0df4-ae2a-446c-a9ba-dbbeb6ffaba5 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2cee61b7-be51-0fe5-e063-6294a90af9e3 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:80501b71-2f08-2ef5-e053-2991aa0a6e86 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:362fb864-3afb-4841-a7c4-b64b1346aba0 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:95479f18-76dc-41cf-a359-922febeed0f2 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9b59428a-a23a-b2d9-982f-98f8a1ed381f (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:529ac72c-c4a0-4001-8cf9-b94f5bf7265c (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4be13bd5-0c39-43c3-9232-b1226ccd4dbc (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fc165a6d-24b0-4753-a7ac-94a134dca0d3 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:301ecffc-ecaf-01de-e063-6294a90a61b3 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b8ac5047-5203-42c4-886b-dd0b08a1786f (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a5ae33ad-4703-4cb2-8618-6439c906be99 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2e32a8aa-047b-46c6-b67b-d88a9a0a810b (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7a12135e-cbad-4fe1-98f7-53c41d1f2a21 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:46a3c619-b2a3-3f28-e063-6394a90a2309 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0a0fd993-7bea-42d8-e063-6394a90a4e0e (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:631523e7-7d67-0cc3-e053-2a91aa0abb62 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0948bff7-efc6-4f0e-a9dd-adca5bdc7fc2 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b001d60e-b8fb-54ff-e053-2a95a90a2970 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:067e260c-dc47-4957-a9ff-5a79f17b4ca0 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f14cf651-a213-4a4f-adb9-f628562af27c (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
Projected row 848
- Medicine slug
- levofloxacin
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 76
- Source count
- 71
- Agreement rate
- 1
- Recorded readings
1 hour
- Numeric value
- 1
- Unit
- hours
- Source records
- 71
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 71 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cbd5153f-fada-4682-b858-dc3b6e3173cc (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Oral administration of a 500 mg dose of levofloxacin with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:af4b7333-4f77-4ec9-e053-2a95a90a16d2 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Oral administration of a 500 mg dose levofloxacin with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bfe280be-0789-69fa-e053-2a95a90a0e13 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Oral administration of a 500 mg dose of levofloxacin with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:64141d0d-0347-470f-a427-9925a2eb357e (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Oral administration of a 500 mg dose of levofloxacin with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b8defac4-9deb-433b-928e-0ef4ee0123a2 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Oral administration of a 500 mg dose of levofloxacin with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c6027cde-b9fe-e593-e053-2995a90ac2c1 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Oral administration of a 500 mg dose levofloxacin with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dabedb15-5b55-3853-e053-2995a90aa44e (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Oral administration of a 500 mg dose levofloxacin with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:54a02488-586d-4c4e-8a35-68a067bdd6e3 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Oral administration of a 500 mg dose levofloxacin with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4a405103-41e8-6a1f-e054-00144ff8d46c (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Oral administration of a 500 mg dose of levofloxacin with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ba69722b-d7f2-4519-8a63-9ee91294c499 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Oral administration of a 500 mg dose of Levofloxacin with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8423b021-e09c-4f1c-e053-2991aa0afef6 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Oral administration of a 500 mg dose levofloxacin with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4d400bf9-988f-42ec-93f1-e71a93a324b2 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Oral administration of a 500 mg dose of levofloxacin with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f2f090c2-3ee1-7689-e053-2995a90abe38 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Oral administration of a 500 mg dose of levofloxacin with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9020cdeb-65fe-458f-bbbd-69265a49906e (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Oral administration of a 500 mg dose of levofloxacin with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5261da15-1b6c-fbe2-e063-6394a90ad85e (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Oral administration of a 500 mg dose of levofloxacin with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:699fbdb8-a6fd-476a-9b80-08197d869534 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Oral administration of a 500 mg dose of levofloxacin with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:95149cfb-1a71-42b7-b50d-9a2e94334339 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Oral administration of a 500 mg dose of levofloxacin with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:171ab6c6-8eb5-4716-926f-cee52b7d0968 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Oral administration of a 500 mg dose levofloxacin with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:05d179f5-b200-8597-e063-6394a90a10cc (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Oral administration of a 500 mg dose levofloxacin with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:264a3f71-f23e-45e3-926a-421bcccf4e3d (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Oral administration of a 500 mg dose of levofloxacin with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:070375be-3b67-4299-ae8f-4a7b157ac16f (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Oral administration of a 500 mg dose of levofloxacinwith food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5c6c117c-9d91-48f4-9aaa-ee70b99218c2 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Oral administration of a 500 mg dose of levofloxacin tablet with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:59f387a4-4dfa-ba71-e063-6294a90a340c (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Oral administration of a 500 mg dose of levofloxacin with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a894e40b-77e4-439b-b0f8-9a5cc7a1dd90 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Oral administration of a 500 mg dose of levofloxacin with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b1a4aabb-42af-4133-8e82-0c7ec8fa79c3 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Oral administration of a 500 mg dose of levofloxacin with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:857f256c-88ac-4f73-9815-c2724edf2f1e (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Oral administration of a 500 mg dose of levofloxacin with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eb30fafa-bbb9-458f-89df-ae610fa6aa96 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Oral administration of a 500 mg dose of levofloxacin with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:804ec547-5b89-4fd0-89b3-7445543e563e (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Oral administration of a 500 mg dose levofloxacin with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bdc8b2cc-a914-4613-ac7c-e8dfe91dea13 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Oral administration of a 500 mg dose levofloxacin with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:afd5cb35-4232-f8b1-e053-2a95a90a8c5b (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Oral administration of a 500 mg dose of levofloxacin with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2a4e97e0-0709-411b-92e8-6f7d669412e4 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Oral administration of a 500 mg dose levofloxacin with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:710c0c10-89a5-4954-8f74-acc187c5cf0f (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Oral administration of a 500 mg dose of levofloxacin with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bcad1dad-53aa-43dd-90f3-cc17cc9598d5 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Oral administration of a 500 mg dose levofloxacin with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f33140d5-59ad-3379-e053-2995a90ae286 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Oral administration of a 500 mg dose of levofloxacin with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:30958610-3803-45e6-aa3c-d256decbe6e4 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Oral administration of a 500 mg dose of levofloxacin with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d98cf024-51fa-45a1-b247-da55aba88ca0 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Oral administration of a 500 mg dose levofloxacin with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ac4001ca-882f-4d9b-a570-c1b9d7fd6830 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Oral administration of a 500 mg dose of levofloxacinwith food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5a1534af-aa1c-4f1d-ba9f-9415b14e1af2 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Oral administration of a 500 mg dose of levofloxacin with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:16d51c1c-4144-4be7-9356-98fcee621ecd (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Oral administration of a 500 mg dose levofloxacin with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f780bb91-483a-d1a6-e053-6294a90ab74b (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Oral administration of a 500 mg dose of levofloxacin with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:44f31105-5fc9-43d4-e063-6294a90a510f (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Oral administration of a 500 mg dose of levofloxacin with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2a8676a9-247f-4fdb-b644-e9785d98771f (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Oral administration of a 500 mg dose levofloxacin with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9f944b63-9b60-437a-ba57-d14d7976bc32 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Oral administration of a 500 mg dose of levofloxacin with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4f40d5fa-ebcc-516c-e054-00144ff8d46c (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Oral administration of a 500 mg dose of levofloxacin with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b7a614b0-f604-48e1-9919-21da8f939d93 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Oral administration of a 500 mg dose of levofloxacin with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:72cb9372-e9f8-3ca1-e053-2a91aa0ad820 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Oral administration of a 500 mg dose of levofloxacin with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b43e9b51-568c-4d84-bbd1-d237120056c4 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Oral administration of a 500 mg dose levofloxacin with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:814450ae-439e-4a5d-8c60-9b21b6f14be5 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Oral administration of a 500 mg dose of levofloxacin with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:427a2077-5dbb-3c5e-e063-6294a90a0839 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Oral administration of a 500 mg dose levofloxacin with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b9dc8bf3-97d9-4d1c-9a68-3ae553acdada (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Oral administration of a 500 mg dose of levofloxacin with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1538ec66-f385-401e-8cfb-d794691e7176 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Oral administration of a 500 mg dose levofloxacin with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2cee61b7-be51-0fe5-e063-6294a90af9e3 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Oral administration of a 500 mg dose of levofloxacin with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:80501b71-2f08-2ef5-e053-2991aa0a6e86 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Oral administration of a 500 mg dose of levofloxacin with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:362fb864-3afb-4841-a7c4-b64b1346aba0 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Oral administration of a 500 mg dose of levofloxacin with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:95479f18-76dc-41cf-a359-922febeed0f2 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Oral administration of a 500 mg dose of Levofloxacin with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9b59428a-a23a-b2d9-982f-98f8a1ed381f (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Oral administration of a 500 mg dose of levofloxacin with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:529ac72c-c4a0-4001-8cf9-b94f5bf7265c (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Oral administration of a 500 mg dose of levofloxacin with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4be13bd5-0c39-43c3-9232-b1226ccd4dbc (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Oral administration of a 500 mg dose of levofloxacin with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fc165a6d-24b0-4753-a7ac-94a134dca0d3 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Oral administration of a 500 mg dose of levofloxacin with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:301ecffc-ecaf-01de-e063-6294a90a61b3 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Oral administration of a 500 mg dose of levofloxacin with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b8ac5047-5203-42c4-886b-dd0b08a1786f (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Oral administration of a 500 mg dose levofloxacin with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a5ae33ad-4703-4cb2-8618-6439c906be99 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Oral administration of a 500 mg dose of levofloxacin with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2e32a8aa-047b-46c6-b67b-d88a9a0a810b (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Oral administration of a 500 mg dose of levofloxacin with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7a12135e-cbad-4fe1-98f7-53c41d1f2a21 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Oral administration of a 500 mg dose of levofloxacin with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:46a3c619-b2a3-3f28-e063-6394a90a2309 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Oral administration of a 500 mg dose levofloxacin with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0a0fd993-7bea-42d8-e063-6394a90a4e0e (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Oral administration of a 500 mg dose of levofloxacin with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:631523e7-7d67-0cc3-e053-2a91aa0abb62 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Oral administration of a 500 mg dose of levofloxacin with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0948bff7-efc6-4f0e-a9dd-adca5bdc7fc2 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Oral administration of a 500 mg dose of levofloxacin with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b001d60e-b8fb-54ff-e053-2a95a90a2970 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Oral administration of a 500 mg dose levofloxacin with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:067e260c-dc47-4957-a9ff-5a79f17b4ca0 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Oral administration of a 500 mg dose of levofloxacin with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f14cf651-a213-4a4f-adb9-f628562af27c (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Oral administration of a 500 mg dose of levofloxacin with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration.
Projected row 849
- Medicine slug
- levofloxacin
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 76
- Source count
- 74
- Agreement rate
- 1
- Recorded readings
74 to 112 L
- Numeric value
- 74
- Unit
- L
- Source records
- 74
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 74 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cbd5153f-fada-4682-b858-dc3b6e3173cc (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:af4b7333-4f77-4ec9-e053-2a95a90a16d2 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bfe280be-0789-69fa-e053-2a95a90a0e13 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:64141d0d-0347-470f-a427-9925a2eb357e (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Figure 2: Mean Levofloxacin Plasma Concentration vs.Time Profile: 750 mg 3: Mean Levofloxacin Plasma Concentration vs.Time Profile: 500 mg Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b8defac4-9deb-433b-928e-0ef4ee0123a2 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:70c87464-1806-480a-8ebd-3f02987ff436 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Figure 2: Mean Levofloxacin Plasma Concentration vs. Time Profile: 750 mg Figure 3: Mean Levofloxacin Plasma Concentration vs. Time Profile: 500 mg Figure 2 Figure 3 Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c6027cde-b9fe-e593-e053-2995a90ac2c1 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dabedb15-5b55-3853-e053-2995a90aa44e (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:54a02488-586d-4c4e-8a35-68a067bdd6e3 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4a405103-41e8-6a1f-e054-00144ff8d46c (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Figure 2: Mean Levofloxacin Plasma Concentration vs.Time Profile: 750 mg Figure 3: Mean Levofloxacin Plasma Concentration vs.Time Profile: 500 mg Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ba69722b-d7f2-4519-8a63-9ee91294c499 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Figure 2: Mean Levofloxacin Plasma Concentration vs. Time Profile: 750 mg Figure 3: Mean Levofloxacin Plasma Concentration vs. Time Profile: 500 mg Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8423b021-e09c-4f1c-e053-2991aa0afef6 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4d400bf9-988f-42ec-93f1-e71a93a324b2 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f2f090c2-3ee1-7689-e053-2995a90abe38 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9020cdeb-65fe-458f-bbbd-69265a49906e (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Figure 2: Mean Levofloxacin Plasma Concentration vs. Time Profile: 750 mg Figure 3: Mean Levofloxacin Plasma Concentration vs. Time Profile: 500 mg Figure 2 Figure 3 Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5261da15-1b6c-fbe2-e063-6394a90ad85e (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:699fbdb8-a6fd-476a-9b80-08197d869534 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Figure 2: Mean Levofloxacin Plasma Concentration vs. Time Profile: 750 mg Figure 3: Mean Levofloxacin Plasma Concentration vs. Time Profile: 500 mg Figure 2 Figure 3 Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e680c759-16c5-4532-9c9c-f42c8c3df74a (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Figure 2: Mean Levofloxacin Plasma Concentration vs. Time Profile: 750 mg Figure 3: Mean Levofloxacin Plasma Concentration vs. Time Profile: 500 mg Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:95149cfb-1a71-42b7-b50d-9a2e94334339 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Figure 2: Mean Levofloxacin Plasma Concentration vs.Time Profile: 750 mg Figure 3: Mean Levofloxacin Plasma Concentration vs.Time Profile: 500 mg Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:171ab6c6-8eb5-4716-926f-cee52b7d0968 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:05d179f5-b200-8597-e063-6394a90a10cc (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:264a3f71-f23e-45e3-926a-421bcccf4e3d (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:070375be-3b67-4299-ae8f-4a7b157ac16f (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5c6c117c-9d91-48f4-9aaa-ee70b99218c2 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:59f387a4-4dfa-ba71-e063-6294a90a340c (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a894e40b-77e4-439b-b0f8-9a5cc7a1dd90 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b1a4aabb-42af-4133-8e82-0c7ec8fa79c3 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:857f256c-88ac-4f73-9815-c2724edf2f1e (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eb30fafa-bbb9-458f-89df-ae610fa6aa96 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:804ec547-5b89-4fd0-89b3-7445543e563e (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bdc8b2cc-a914-4613-ac7c-e8dfe91dea13 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:afd5cb35-4232-f8b1-e053-2a95a90a8c5b (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2a4e97e0-0709-411b-92e8-6f7d669412e4 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:710c0c10-89a5-4954-8f74-acc187c5cf0f (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bcad1dad-53aa-43dd-90f3-cc17cc9598d5 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f33140d5-59ad-3379-e053-2995a90ae286 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:30958610-3803-45e6-aa3c-d256decbe6e4 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d98cf024-51fa-45a1-b247-da55aba88ca0 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ac4001ca-882f-4d9b-a570-c1b9d7fd6830 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5a1534af-aa1c-4f1d-ba9f-9415b14e1af2 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Figure 2: Mean Levofloxacin Plasma Concentration vs. Time Profile: 750 mg Figure 3: Mean Levofloxacin Plasma Concentration vs. Time Profile: 500 mg Figure 2 Figure 3 Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:16d51c1c-4144-4be7-9356-98fcee621ecd (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f780bb91-483a-d1a6-e053-6294a90ab74b (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:44f31105-5fc9-43d4-e063-6294a90a510f (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2a8676a9-247f-4fdb-b644-e9785d98771f (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9f944b63-9b60-437a-ba57-d14d7976bc32 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4f40d5fa-ebcc-516c-e054-00144ff8d46c (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
2] [levofloxacinfigure2] Figure 3: Mean Levofloxacin Plasma Concentration vs.Time Profile: 500 mg [levofloxacinfigure3] [levofloxacinfigure3] Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b7a614b0-f604-48e1-9919-21da8f939d93 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:72cb9372-e9f8-3ca1-e053-2a91aa0ad820 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Figure 2: Mean Levofloxacin Plasma Concentration vs.Time Profile: 750 mg Figure 3: Mean Levofloxacin Plasma Concentration vs.Time Profile: 500 mg Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b43e9b51-568c-4d84-bbd1-d237120056c4 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:814450ae-439e-4a5d-8c60-9b21b6f14be5 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:427a2077-5dbb-3c5e-e063-6294a90a0839 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b9dc8bf3-97d9-4d1c-9a68-3ae553acdada (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1538ec66-f385-401e-8cfb-d794691e7176 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f23c0df4-ae2a-446c-a9ba-dbbeb6ffaba5 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Figure 2: Mean Levofloxacin Plasma Concentration vs. Time Profile: 750 mg Figure 3: Mean Levofloxacin Plasma Concentration vs. Time Profile: 500 mg Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2cee61b7-be51-0fe5-e063-6294a90af9e3 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:80501b71-2f08-2ef5-e053-2991aa0a6e86 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Figure 2: Mean Levofloxacin Plasma Concentration vs.Time Profile: 750 mg Figure 3: Mean Levofloxacin Plasma Concentration vs.Time Profile: 500 mg Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:362fb864-3afb-4841-a7c4-b64b1346aba0 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Figure 2: Mean Levofloxacin Plasma Concentration vs. Time Profile: 750 mg Figure 3: Mean Levofloxacin Plasma Concentration vs. Time Profile: 500 mg Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:95479f18-76dc-41cf-a359-922febeed0f2 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Figure 2: Mean Levofloxacin Plasma Concentration vs. Time Profile: 750 mg Figure 3: Mean Levofloxacin Plasma Concentration vs. Time Profile: 500 mg Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9b59428a-a23a-b2d9-982f-98f8a1ed381f (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:529ac72c-c4a0-4001-8cf9-b94f5bf7265c (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4be13bd5-0c39-43c3-9232-b1226ccd4dbc (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fc165a6d-24b0-4753-a7ac-94a134dca0d3 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:301ecffc-ecaf-01de-e063-6294a90a61b3 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b8ac5047-5203-42c4-886b-dd0b08a1786f (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a5ae33ad-4703-4cb2-8618-6439c906be99 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2e32a8aa-047b-46c6-b67b-d88a9a0a810b (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7a12135e-cbad-4fe1-98f7-53c41d1f2a21 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:46a3c619-b2a3-3f28-e063-6394a90a2309 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0a0fd993-7bea-42d8-e063-6394a90a4e0e (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:631523e7-7d67-0cc3-e053-2a91aa0abb62 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Figure 2: Mean Levofloxacin Plasma Concentration vs.Time Profile: 750 mg Figure 3: Mean Levofloxacin Plasma Concentration vs.Time Profile: 500 mg Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0948bff7-efc6-4f0e-a9dd-adca5bdc7fc2 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b001d60e-b8fb-54ff-e053-2a95a90a2970 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:067e260c-dc47-4957-a9ff-5a79f17b4ca0 (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f14cf651-a213-4a4f-adb9-f628562af27c (opens source in a new tab)
Levofloxacin label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
Projected row 850
- Medicine slug
- levoleucovorin
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 9
- Source count
- 8
- Agreement rate
- 1
- Recorded readings
5.1 hours
- Numeric value
- 5.1
- Unit
- hours
- Source records
- 8
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 8 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:54f01988-aac2-4b0e-9d20-b7f621a0cd50 (opens source in a new tab)
Levoleucovorin label
Version not recorded · Effective date not recorded
Elimination The mean terminal half-life was 5.1 hours for total-THF and 6.8 hours for (6S)-5-methyl-5,6,7,8-tetrahydrofolate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dbb3613c-78a9-4a96-a766-17e7a9e8809b (opens source in a new tab)
Levoleucovorin label
Version not recorded · Effective date not recorded
Elimination The mean terminal half-life was 5.1 hours for total-THF and 6.8 hours for (6S)-5-methyl-5,6,7,8-tetrahydrofolate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0c67eeae-3090-473d-b712-b9a83dc77b72 (opens source in a new tab)
Levoleucovorin label
Version not recorded · Effective date not recorded
Elimination The mean terminal half-life was 5.1 hours for total-THF and 6.8 hours for (6S)-5-methyl-5,6,7,8-tetrahydrofolate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:059a3306-6207-497f-a947-33198f18761f (opens source in a new tab)
Levoleucovorin label
Version not recorded · Effective date not recorded
Elimination The mean terminal half-life was 5.1 hours for total-THF and 6.8 hours for (6S)-5-methyl-5,6,7,8-tetrahydrofolate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c10b0c18-dd7c-4a76-a79b-b8d38a08ab87 (opens source in a new tab)
Levoleucovorin label
Version not recorded · Effective date not recorded
Elimination The mean terminal half-life was 5.1 hours for total-THF and 6.8 hours for (6S)-5-methyl-5,6,7,8-tetrahydrofolate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:124bc214-62f8-40f9-a227-a35e2d1ff2a0 (opens source in a new tab)
Levoleucovorin label
Version not recorded · Effective date not recorded
Elimination The mean terminal half-life was 5.1 hours for total-THF and 6.8 hours for (6S)-5-methyl-5,6,7,8-tetrahydrofolate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b4dd0e14-d42a-4581-b1f0-7ba95b50bca6 (opens source in a new tab)
Levoleucovorin label
Version not recorded · Effective date not recorded
Elimination The mean terminal half-life was 5.1 hours for total-THF and 6.8 hours for (6S)-5-methyl-5,6,7,8-tetrahydrofolate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:344f65ac-9f04-49d7-b7c3-4ba19bd7b429 (opens source in a new tab)
Levoleucovorin label
Version not recorded · Effective date not recorded
Elimination The mean terminal half-life was 5.1 hours for total-THF and 6.8 hours for (6S)-5-methyl-5,6,7,8-tetrahydrofolate.
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=840Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.